Mobile website
Clinical Research
Expression of CD133 in pancreatic cancer tissues and its clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To investigate the expression of CD133 (also known as PROM1) in pancreatic cancer tissues and its association with clinicopathological features and prognosis of pancreatic cancer patients. Methods: The GEPIA website was used to analyze the expression of CD133 in pancreatic cancer patients from the TCGA database. The correlation between PROM1 mRNA expression and cancer stem cell family genes in human pancreatic cancer tissues was analyzed based on the TCGA database. The expression of CD133 in pancreatic cancer tissues and its clinical significance were studied by immunohistochemistry (IHC) staining. Wilcoxon rank sum test was used to analyze the difference in CD133 expression between pancreatic cancer tissues and adjacent tissues. Chi-square test was used to analyze the relationship between CD133 expression and clinicopathological characteristics in pancreatic cancer tissues. KaplanMeier method and Log-rank test were used to analyze the survival difference based on different levels of CD133 expression in pancreatic cancer tissues. The Cox model was used to evaluate the prognostic value of different indicators. Hazard ratio (HR) and 95% confidence interval (95% CI) were used to assess the strength of the association between CD133 expression and mortality risk in pancreatic cancer patients. Results: TCGA database analysis showed that the expression of CD133 was significantly up-regulated in pancreatic cancer tissues compared with adjacent tissues (P < 0.05). The mRNA expression level of PROM1 in pancreatic cancer tissues was correlated with tumor stem cell family genes, including EPCAM, POU5F1, CD24, CD44 and CXCR4. The expression level of CD133 in pancreatic cancer tissues was significantly associated with tumor differentiation, TNM stage, and lymph node metastasis (all P < 0.05). Univariate Cox model analysis showed that overall survival (OS) was significantly associated with age (HR = 0.544, 95%CI [0.299, 0.990], P < 0.05), depth of invasion (HR = 0.496, 95%CI [0.292, 0.842], P < 0.05), TNM stage (HR = 2.148, 95%CI [1.352,3.412], P < 0.05), and CD133 expression (HR = 1.935, 95%CI [1.090, 3.433], P < 0.05). Multivariate Cox model analysis showed that TNM stage (HR = 0.116, 95%CI [0.025, 0.551], P < 0.05), lymph node metastasis (HR = 0.392, 95%CI [0.160, 0.960], P < 0.05) and CD133 expression (HR = 2.080, 95%CI [1.053, 4.106], P < 0.05) were independent prognostic risk factors. Conclusion: CD133 is highly expressed in pancreatic cancer tissues, and its expression is significantly associated with the prognosis of pancreatic cancer patients. CD133 may serve as a potential new target for immunotherapy in pancreatic cancer.
Keywords:
Project Supported:
Clc Number:
